Mitchell Kuppinger, MD
Pulmonary Disease · Fort Worth, TXNPI 1174517809
Payments from drug & device makers
Across 48 payments — averaging $320.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Mallinckrodt Enterprises LLC$4K
- GSK$3K
- Inspire Medical Systems, Inc.$266
- Harmony Biosciences LLC$116
- Jazz Pharmaceuticals Inc.$74
- plus $477 from 14 others
What the payments were for
- Food & beverage$1,02892%
- Education$958%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $7,852 |
| Mallinckrodt Enterprises LLC | 1 | $4,000 |
| GSK | 7 | $2,592 |
| Inspire Medical Systems, Inc. | 7 | $266 |
| Harmony Biosciences LLC | 2 | $116 |
| Jazz Pharmaceuticals Inc. | 3 | $74 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| ZOLL Respicardia, Inc. | 2 | $58 |
| Philips North America LLC | 3 | $55 |
| Boehringer Ingelheim | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Insmed, Inc. | 2 | $41 |
| Fisher & Paykel Healthcare Inc | 1 | $32 |
| Vifor Pharma, Inc. | 1 | $27 |
| Merck | 1 | $23 |
| Resmed Corp | 1 | $20 |
| AbbVie | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
How this compares
$15,378 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ropinirole Hcl | 18 | $270 |
| Montelukast Sodium | 26 | $199 |
| Gabapentin | 15 | $193 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Fort Worth
- Sherif Al-FarraFort Worth$443K
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.